In short
Recent clinical trials have been exploring the potential of Coffee Charcoal, in combination with other natural ingredients, as a treatment for Irritable Bowel Syndrome (IBS). These studies focus on the efficacy and safety of MYRRHINIL-INTEST®, a medication containing Coffee Charcoal, Myrrh, and Chamomile extract, in managing symptoms of diarrhea-predominant IBS (IBS-D) and mixed-type IBS (IBS-M). The trials aim to provide valuable insights into this alternative treatment approach for patients suffering from these challenging gastrointestinal conditions.
At a glance
- Study Drug
- MYRRHINIL-INTEST® (containing Coffee Charcoal, Myrrh, and Chamomile extract)
- Target Conditions
- Diarrhea-predominant IBS (IBS-D) and Mixed-type IBS (IBS-M)
- Participant Age Range
- 18-75 years
- Primary Objectives
- Assess efficacy, safety, and tolerability compared to placebo
- Key Measurements
- Abdominal pain, stool consistency, quality of life, global improvement
- Study Duration
- Up to 8 weeks of treatment
- Dosage
- Up to 12 coated tablets daily
- Key Exclusions
- Inflammatory bowel diseases, diabetes, thyroid disorders, pregnancy
What is Coffee Charcoal?
Coffee charcoal, also known as Coffeae carbo, is a medicinal ingredient derived from coffee beans that have been processed into a charcoal form. It is one of the key components in a medication called MYRRHINIL-INTEST®, which is being studied for its potential benefits in treating certain digestive disorders.
Medical Conditions Treated
MYRRHINIL-INTEST®, which contains coffee charcoal, is primarily being investigated for the treatment of two types of Irritable Bowel Syndrome (IBS):
- Diarrhea-predominant IBS (IBS-D): A condition characterized by frequent loose or watery stools.
- Mixed-type IBS (IBS-M): A condition where patients experience both diarrhea and constipation.
These conditions are chronic digestive disorders that can significantly impact a person's quality of life, causing symptoms such as abdominal pain, changes in bowel habits, and bloating.
Composition and Formulation
MYRRHINIL-INTEST® is a combination medication that includes three main ingredients:
- Coffee charcoal: 50 mg
- Myrrh: 100 mg
- Dry extract from chamomile flower: 70 mg
The medication comes in the form of coated tablets, which are designed to be taken orally.
How It Works
While the exact mechanism of action is still being studied, it is believed that the combination of coffee charcoal, myrrh, and chamomile extract works together to alleviate IBS symptoms. Coffee charcoal may help absorb excess gas and toxins in the digestive tract, while myrrh and chamomile are known for their anti-inflammatory and soothing properties.
Dosage and Administration
According to the clinical trials, the maximum daily dose of MYRRHINIL-INTEST® is 12 coated tablets. The total treatment period in the studies lasted up to 8 weeks. However, it's important to note that this dosage is specific to the clinical trials and may not reflect the final recommended dosage if the medication becomes approved for general use.
Clinical Trials
MYRRHINIL-INTEST® is currently being evaluated in controlled clinical trials to investigate its efficacy and safety for patients with IBS-D and IBS-M. These trials aim to determine whether the medication can effectively reduce abdominal pain, improve stool consistency, and enhance overall bowel health compared to a placebo.
Potential Benefits
If proven effective, MYRRHINIL-INTEST® could offer several benefits for IBS patients:
- Reduction in abdominal pain
- Improvement in stool consistency
- Decrease in the frequency of diarrhea episodes
- Better overall bowel health
- Improved quality of life for those suffering from IBS-D or IBS-M
However, it's important to remember that these potential benefits are still being evaluated in clinical trials.
Side Effects and Precautions
As with any medication, there may be potential side effects and precautions to consider. The clinical trials are designed to assess the safety and tolerability of MYRRHINIL-INTEST®. Patients with known hypersensitivity to any of the ingredients (coffee charcoal, myrrh, or chamomile) should not take this medication. Additionally, the trials exclude patients with certain medical conditions, such as inflammatory bowel diseases, to ensure the safety of participants.
It's crucial to note that MYRRHINIL-INTEST® is still under investigation, and its full safety profile and efficacy have not yet been established. Patients should always consult with their healthcare provider before considering any new treatment for IBS or other digestive disorders.